SuperworthDanaher DHR
- Market cap
- $162B
- PE
- 40.9×
- 10y median 34.2×
- Forward PE
- 25.4×
- 10y median 25.6×
- Price to sales
- 6.5×
- EV/EBIT
- 34.5×
- Revenue, 12 months
- $25.1B
- +5% on a year ago
- Net margin
- 15.9%
- Free cash flow yield
- 3.4%
Danaher trades at 40.9× trailing earnings, pricier than 82% of the last ten years. Revenue was $25.1B over the last twelve months, up 5% on a year earlier with a 16% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $5.6B−13% | $6.4B−10% | $5.8B−3% | $5.7B−3% | $5.8B+3% | $6.5B+2% | $5.7B−1% | $5.9B+3% | $6.1B+4% | $6.8B+5% | $6B+4% | $6.3B+6% | |
| Cost of revenue | $2.3B−24% | $2.6B−23% | $2.3B+1% | $2.3B−11% | $2.4B+2% | $2.6B+1% | $2.2B−3% | $2.4B+4% | $2.5B+6% | $2.9B+9% | $2.4B+6% | $2.7B+10% |
| Gross profit | $3.3B−16% | $3.8B−11% | $3.5B−5% | $3.4B+3% | $3.4B+4% | $3.9B+3% | $3.5B+1% | $3.5B+3% | $3.5B+4% | $4B+2% | $3.6B+2% | $3.6B+3% |
| R&D | $362M−14% | $407M−10% | $368M−1% | $391M+8% | $383M+6% | $442M+9% | $379M+3% | $403M+3% | $378M−1% | $438M−1% | $387M+2% | $412M+2% |
| SG&A | $1.7B−20% | $2B−7% | $1.8B+2% | $1.9B+4% | $2.1B+19% | $2B−1% | $1.9B+3% | $2.4B+26% | $2B−3% | $2B+0% | $1.9B+0% | $2.1B−12% |
| $1.2B−31% | $1.3B−33% | $1.3B−14% | $1.2B+0% | $958M−19% | $1.4B+7% | $1.3B−3% | $760M−35% | $1.2B+21% | $1.5B+5% | $1.3B+6% | $1.1B+48% | |
| Interest expense | $70M+67% | $85M+33% | $65M−2% | $65M+0% | $87M+24% | $61M−28% | $72M+11% | $71M+9% | $67M−23% | $55M−10% | $63M−13% | $107M+51% |
| Pre-tax income | $1.1B−41% | $1.2B−44% | $1.3B−17% | $1.1B−5% | $977M−15% | $1.3B+7% | $1.1B−11% | $655M−40% | $1.1B+10% | $1.4B+4% | $1.2B+9% | $1.1B+65% |
| $207M−42% | $111M | $183M−35% | $176M−21% | $159M−23% | $229M+106% | $175M−4% | $100M−43% | $168M+6% | $190M−17% | $206M+18% | $208M+108% | |
| Net income | $1.1B−28% | $1.1B−52% | $1.1B−25% | $907M−18% | $818M−28% | $1.1B+1% | $954M−12% | $555M−39% | $908M+11% | $1.2B+10% | $1B+8% | $870M+57% |
| $1.51−28% | $1.45−52% | $1.45−25% | $1.22−18% | $1.12−26% | $1.49+3% | $1.32−9% | $0.77−37% | $1.27+13% | $1.68+13% | $1.45+10% | $1.23+60% | |
| 745.9M+1% | 746M+0% | 748.6M+2% | 742.4M−0% | 729.4M−2% | 728.2M−2% | 720.8M−4% | 719.1M−3% | 713.7M−2% | 711M−2% | 711.2M−1% | 707.6M−2% |
Gross profit: 5 periods, Q2 FY08 to Q2 FY09: not printed by the filing, worked out from its own lines.
Net income: 6 periods, Q4 FY09 to Q4 FY25: printed in the fourth-quarter results release.
EPS, diluted: Q4 FY08: quarter's net income to common over its shares, to the cent. 6 periods, Q4 FY09 to Q4 FY25: printed in the fourth-quarter results release.
Diluted shares: 12 periods, Q4 FY08 to Q4 FY23: share-days: the 12-month average less the 9-month, weighted by days. 6 periods, Q4 FY09 to Q4 FY25: printed in the fourth-quarter results release.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Estimates
Next earnings report: .
| Quarter | Revenue | Range | EPS | Range | Analysts |
|---|---|---|---|---|---|
| Q3 FY26 | $6.6B | $6.5B to $6.6B | $1.92 | $1.91 to $1.95 | 13 |
| Q4 FY26 | $7.5B | $7.1B to $7.7B | $2.48 | $2.44 to $2.58 | 14 |
| Q1 FY27 | $6.6B | $6.4B to $6.8B | $2.24 | $2.18 to $2.30 | 9 |
| Q2 FY27 | $6.9B | $6.7B to $7B | $2.13 | $2.05 to $2.18 | 4 |
| Q3 FY27 | $6.9B | $6.7B to $7B | $2.24 | $2.15 to $2.29 | 7 |
| Q4 FY27 | $7.8B | $7.6B to $8B | $2.67 | $2.57 to $2.73 | 3 |
| Q1 FY28 | $7B | $6.8B to $7.1B | $2.44 | $2.35 to $2.49 | 4 |
| Q2 FY28 | $7.2B | $7B to $7.3B | $2.29 | $2.20 to $2.34 | 6 |
Peers
Companies in Medical - Diagnostics & Research nearest Danaher's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| DHRDanaher | $162B | 40.9× | 34.2× | 25.4× | 6.5× | +5% | 15.9% |
| TMOThermo Fisher Scientific | $249.1B | 35.5× | 33.0× | 25.0× | 5.3× | +8% | 14.9% |
| AAgilent Technologies | $48.8B | 34.0× | 33.1× | 26.4× | 6.6× | +9% | 19.5% |
| IQVIQVIA | $46B | 34.7× | 34.9× | 20.5× | 2.7× | +8% | 8.1% |
| WATWaters | $44.6B | 113× | 29.2× | 29.2× | 9.6× | +52% | 3.6% |
| IDXXIDEXX Laboratories | $44.1B | 39.4× | 55.0× | 35.9× | 9.7× | +13% | 25.0% |
| ILMNIllumina | $40.7B | 50.1× | 51.4× | 47.2× | 9.1× | +5% | 18.4% |
| MTDMettler-Toledo International | $33.5B | 37.6× | 36.5× | 33.9× | 8.1× | +7% | 21.9% |
| DGXQuest Diagnostics | $26.7B | 25.7× | 19.3× | n/m | 2.3× | +9% | 9.2% |
| LHLabcorp | $26.7B | 27.2× | 19.4× | 17.4× | 1.9× | +6% | 7.0% |
| MEDPMedpace | $18.7B | 39.2× | 34.5× | n/m | 6.7× | +25% | 17.7% |
| Peer median | $42.4B | 36.6× | 33.8× | 27.8× | 6.7× | +8% | 16.3% |
Investors who own it
Investors we follow who held Danaher at the end of Jun 30, 2026, from their 13F filings.
- Dan LoebThird Point2.2% of portfolioadded
- Dan SundheimD1 Capital Partners1.2% of portfoliotrimmed
- Chase ColemanTiger Global Management0.4% of portfolionew
- Stanley DruckenmillerDuquesne Family Office0.2% of portfolionew
- Bill NygrenHarris Associates (Oakmark)0.0% of portfolio
- Baillie GiffordBaillie Gifford0.0% of portfolionew
More on Danaher
Each number over time
- PE ratio
- Forward PE
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Dividend yield
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #9of 39Diagnostics and research stocks with the highest profit margins
- #4of 17Diagnostics and research stocks with the fastest earnings growth
- #4of 11Diagnostics and research stocks with the fastest expected revenue growth
- #10of 15Diagnostics and research stocks cheapest against their own PE history
Its groups
About
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .